___________________________________________________________________________ Colorectal Cancer 147. Simmons DT, Harewood GC, Baron TH, et al. Impact of endoscopist withdrawal speed on polyp yield: implications for optimal colonoscopy withdrawal time. Aliment Pharmacol Ther . 2006;24(6):965-971. 148. Lim G, Viney SK, Chapman BA, Frizelle FA, Gearry RB. A prospective study of endoscopist-blinded colonoscopy withdrawal times and polyp detection rates in a tertiary hospital. N Z Med J. 2012;125(1356):52-59. 149. Barclay RL, Vicari JJ, Doughty AS, Johanson JF, Greenlaw RL. Colonoscopic withdrawal times and adenoma detection during screening colonoscopy. N Engl J Med . 2006;355(24):2533-2541. 150. National Institute of Diabetes and Digestive and Kidney Diseases. Virtual Colonoscopy. Available at https://www.niddk.nih.gov/ health-information/diagnostic-tests/virtual-colonoscopy. Last accessed March 7, 2022. 151. You JJ, Liu Y, Kirby J, Vora P, Moayyedi P. virtual colonoscopy, optical colonoscopy, or fecal occult blood testing for colorectal cancer screening: results of a pilot randomized controlled trial. Trials . 2015;16:296. 152. Zalis ME, Blake MA, Cai W, et al. Diagnostic accuracy of laxative-free computed tomographic colonography for detection of adenomatous polyps in asymptomatic adults: a prospective evaluation. Ann Intern Med . 2012;156(10):692-702. 153. Kimberly JR, Phillips KC, Santago P, et al. Extracolonic findings at virtual colonoscopy: an important consideration in asymptomatic colorectal cancer screening. J Gen Intern Med . 2009;24(1):69-73. 154. Pickhardt PJ, Hanson ME, Vanness DJ, et al. Unsuspected extracolonic findings at screening CT colonography: clinical and economic impact. Radiology . 2008;249(1):151-159. 155. Maggialetti N, Capasso R, Pinto D, et al. Diagnostic value of computed tomography colonography (CTC) after incomplete optical colonoscopy. Int J Surg . 2016;(33 Suppl 1):S36-S44. 156. National Institute of Diabetes and Digestive and Kidney Diseases. Flexible Sigmoidoscopy. Available at https://www.niddk.nih.gov/ health-information/diagnostic-tests/flexible-sigmoidoscopy. Last accessed March 7, 2022. 157. Levin TR, Palitz A, Grossman S, et al. Predicting advanced proximal colonic neoplasia with screening sigmoidoscopy. JAMA . 1999;281(17):1611-1617. 158. National Cancer Institute. Double-Contrast Barium Enema. Available at https://www.cancer.gov/publications/dictionaries/cancer- terms/def/double-contrast-barium-enema. Last accessed March 7, 2022. 159. National Colorectal Cancer Roundtable. Clinician’s Reference: Fecal Occult Blood Testing (FOBT) for Colorectal Cancer Screening. Available at http://nccrt.org/wp-content/uploads/FOBTCliniciansReferenceFinal.pdf. Last accessed March 7, 2022. 160. Levi Z, Rozen P, Hazazi R, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med . 2007;146(4):244-255. 161. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med . 2014;370:1287-1297. 162. Hewitson P, Glasziou P, Irwig L, Towler B, Watson E. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev . 2007;24(1):CD001216. 163. Qaseem A, Crandell CJ, Mustafa RA, Hicks LA, Wilt TJ. Screening for colorectal cancer in asymptomatic average-risk adults: a guidance statement from the American College of Physicians. Ann Intern Med . 2019;171(9):643-654. 164. Gupta S, Lieberman D, Anderson JC, et al. Recommendations for follow-up after colonoscopy and polypectomy: a consensus update by the U.S. Multi-society Task Force on Colorectal Cancer. Gastrointestinal Endosc . 2020;91(3):463-485. 165. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the U.S. Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin . 2008;58(3):130-160. 166. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut . 2010;59(5):666-690. 167. Singh H, Turner D, Xue L, Targownik LE, Bernstein CN. Risk of developing colorectal cancer following a negative colonoscopy examination. JAMA . 2006;295(20):2366-2373. 168. Robertson DJ, Lieberman DA, Winawer SJ, et al. Interval cancer after total colonoscopy: results from a pooled analysis of eight studies. Gastroenterology . 2008;134(4 Suppl 1):A111-A112. 169. Grady WM, Pritchard CC. Molecular alterations and biomarkers in colorectal cancer. Toxicol Pathol . 2014;42(1):124-139. 170. Al-Sohaily S, Biankin A, Leong R, Kohonen-Corish M, Warusavitarne J. Molecular pathways in colorectal cancer. J Gastroenterol Hepatol . 2012;27(9):1423-1431. 171. BMJ Best Practice. Colorectal Cancer. Available at https://bestpractice.bmj.com/topics/en-us/258. Last accessed March 7, 2022. 172. National Cancer Institute: Surveillance, Epidemiology, and End Results Program. SEER Cancer Statistics Review 1975-2018. Available at https://seer.cancer.gov/csr/1975_2018. Last accessed March 7, 2022. 173. Saclarides TJ, Szeluga D, Staren ED. Neuroendocrine cancers of the colon and rectum: results of a ten-year experience. Dis Colon Rectum . 1994;37(7):635-642. 174. Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol . 2001;96(10):2992- 3003.
Powered by FlippingBook